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OBJECTIVE—Although Smad3 has been considered as a down-
stream mediator of transforming growth factor-b (TGF-b) signal-
ing in diabetes complications, the role of Smad7 in diabetes
remains largely unclear. The current study tests the hypothesis
that Smad7 may play a protective role and has therapeutic poten-
tial for diabetic kidney disease.
RESEARCH DESIGN AND METHODS—P r o t e c t i v er o l eo f
Smad7 in diabetic kidney disease was examined in streptozotocin-
induced diabetic mice that have Smad7 gene knockout (KO) and
in diabetic rats given Smad7 gene transfer using an ultrasound-
microbubble-mediated technique.
RESULTS—We found that mice deﬁcient for Smad7 developed
more severe diabetic kidney injury than wild-type mice as evidenced
by a signiﬁcant increase in microalbuminuria, renal ﬁbrosis (colla-
gen I, IV, and ﬁbronectin), and renal inﬂammation (interleukin-1b
[IL-1b], tumor necrosis factor-a [TNF-a], monocyte chemoattractant
protein-1 [MCP-1], intracellular adhesion molecule-1 [ICAM-1], and
macrophages). Further studies revealed that enhanced renal ﬁbrosis
and inﬂammation in Smad7 KO mice with diabetes were associ-
ated with increased activation of both TGF-b/Smad2/3 and nuclear
factor-kB( N F - kB) signaling pathways. To develop a therapeutic po-
tential for diabetic kidney disease, Smad7 gene was transferred into
the kidney in diabetic rats by an ultrasound-microbubble-mediated
technique. Although overexpression of renal Smad7 had no effect
on levels of blood glucose, it signiﬁcantly attenuated the develop-
ment of microalbuminuria, TGF-b/Smad3-mediated renal ﬁbrosis
such as collagen I and IV and ﬁbronectin accumulation and NF-kB/
p65-driven renal inﬂammation including IL-1b,T N F - a,M C P - 1 ,a n d
ICAM-1 expression and macrophage inﬁltration in diabetic rats.
CONCLUSIONS—Smad7 plays a protective role in diabetic renal
injury. Overexpression of Smad7 may represent a novel therapy
for the diabetic kidney complication. Diabetes 60:590–601, 2011
D
iabetic nephropathy is a major complication
of diabetes (1–4). Approximately 20–40% of
patients with type 1 or type 2 diabetes melli-
tus (DM) develop diabetic nephropathy (5,6).
Diabetic nephropathy is characterized by excessive depo-
sition of extracellular matrix (ECM) proteins in the
mesangium and tubulointerstitium, thickness of basement
membrane of the glomeruli, and loss of podocytes with the
development of microalbuminuria and a decline of renal
function (2,3,7). Both in vivo and in vitro studies have
demonstrated that renal ﬁbrosis and inﬂammation play an
important role in the pathogenesis of diabetic kidney dis-
ease (2–4,7–10). Transforming growth factor-b (TGF-b)
family is a crucial mediator in the development of diabetic
nephropathy (11–15).
It is now clear that after binding to its receptors, TGF-b
signals through two critical downstream mediators, Smad2
and Smad3, to exert its biological activities such as ECM
production. In addition, TGF-b1 also induces an inhibitory
Smad called Smad7, which negatively regulates activation
of Smad2/3 by TGF-b receptor competition and degrada-
tion via the ubiquitin-proteasome degradation mechanism
(16,17). Recent studies have demonstrated that over-
expression of Smad7 is capable of inhibiting renal ﬁbrosis
and inﬂammation by blocking the activation of both TGF-
b/Smad and nuclear factor-kB (NF-kB) signaling pathway
(18–22). In contrast, deletion of Smad7 promotes renal
ﬁbrosis and inﬂammation (23), suggesting that Smad7
may be a key regulator and a therapeutic agent for renal
ﬁbrosis and inﬂammation (24). Although it has been
reported that Smad3 is pathogenic in ﬁbrosis including
diabetic kidney disease (25,26), the role of Smad7 in di-
abetes complications remains unexplored, and it is un-
known whether blockade of the TGF-b signaling pathway
by Smad7 has therapeutic potential for diabetes compli-
cations. Thus, in the current study, we uncovered the role
of Smad7 in diabetic kidney disease induced in Smad7
knockout (KO) mice and developed new therapeutic
strategy for diabetic kidney complication by targeting
the TGF-b/Smad pathway with ultrasound-microbubble-
mediated Smad7 gene therapy.
RESEARCH DESIGN AND METHODS
Animal models. Diabetes was induced in genetically identical littermate
Smad7 KO and wild-type (WT) mice (CD-1 background mice, male, aged 12–14
weeks, 32.91 6 0.80 vs. 43.68 6 1.06 g) by a daily intraperitoneally injection of
50 mg/kg streptozotocin (STZ) for 5 consecutive days as recommended by
Animal Models of Diabetic Complications Consortium (27). Smad7 KO mice
were generated by functionally deleting exon I in the Smad7 gene as pre-
viously described (28), and the genotype was conﬁrmed by PCR with primers
as shown in Supplementary Fig. 1A. Nonfasting blood glucose was monitored
weekly for the ﬁrst 2 weeks after the last STZ injection and then every 4 weeks
by blood glucose meter (Optium Xceed systems, Victoria, Australia). Urinary
samples (16 h) were collected in metabolic cages for microalbuminuria assay.
Groups of eight mice were killed at 24 weeks for examination. In addition,
groups of six normal Smad7 KO and WT mice that received sodium citrate
buffer, instead of STZ, were used as normal age-matched control.
Todevelopatherapeuticstrategyfordiabetickidneydiseasewithultrasound-
microbubble-mediated Smad7 gene transfer, a diabetic rat model was used
because when compared with mice, rats are more sensitive to STZ-induced
diabetic renal injury and more technically feasible for gene delivery via the left
renal artery for 4 weeks as previously described (19). Brieﬂy, experimental
diabetes was induced in Sprague-Dawley rats (male, aged 6 weeks, 220–240 g)
by a single injection of STZ (60 mg/kg i.p.). Groups of six diabetic rats were
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ORIGINAL ARTICLErandomized to three groups: 1) diabetes group (DM), 2) diabetes treated with
empty vector control, and 3) diabetes treated with Smad7 (Smad7) using the
ultrasound-microbubble gene transfer technique as described below. Blood
glucose and 24-h microalbuminuria were examined as described above. All
animals were killed at week 5 after STZ injection. A group of six rats treated
with sodium citrate buffer was used as normal age-matched control. The ex-
perimental protocols for both diabetic models induced in mice or rats were
approved by the Institutional Animal Experimentation Ethics Committee.
Ultrasound-mediated gene transfer of inducible Smad7 gene-bearing
microbubbles into the kidney. An established gene transfer technique using
the ultrasound-mediatedinducibleSmad7gene-bearingmicrobubbleswas used
in this study as described previously (18,19). Brieﬂy, after 1 day STZ injection,
the left rat kidney was transfected with a mixture of pTRE–Flag-M2Smad7 and
pEFpurop-Tet-on with Optison (echo contrast agents, Mallinckrodt, St. Louis,
MO) in 1:1 vol/vol ratio, containing 25 µg of the designated plasmids in 0.5 mL
saline, via the left renal artery with temporarily clipping off the renal blood
supply (,5 min). The ultrasound transducer (Ultax UX-301; Celcom Medico,
Japan) was directly applied onto the left kidney with a continuous-wave
output of 1-MHz ultrasound at 5% power output, for a total of 60 s with 30-s
intervals. Immediately after ultrasound, all animals were received with doxy-
cycline in the drinking water (200 mg/mL) to induce Smad7 expression. Con-
trol animals had the same protocol but received the pTRE/Tet-on empty
vectors without Smad7.
Smad7 gene transfection rate and transgene expression within the kidney
was determined by immunohistochemistry with monoclonal antibody to Flag-
M2, and levels of Smad7 expression were determined by quantitative real-time
PCR, Western blot, and immunohistochemistry with anti-Smad7 antibody as
previously described (18).
Real-time PCR. Renal cortex was collected by carefully removing the renal
pelvis and medullar tissues and was frozen at 280°C freezer for analysis of the
gene of interest by quantitative real-time PCR as previously described (23).
The primers used for detection of both mouse and rat mRNA expression in-
cluding interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a), intracellular
adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1),
TGF-b1, Smad7, collagen I, and GAPDH were described previously (19,23),
whereas the primers for collagen IV and ﬁbronectin were described below:
mouse collagen IV: forward 59-GCAACGGTACAAAGGGAGAGAG-39, reverse
59-CTTCATTCCTGGTAACCCTGGTG-39; mouse ﬁbronectin: forward 59-TACC
AAGGTCAATCCACACCCC-39, reverse 59-CAGATGGCAAAAGAAAGCAGAGG-39;
rat ﬁbronectin: forward 59-TCTATCCAGGGAGGGCAGTGT-39, reverse 5-GTT
TGCCAAGGGCTCATCTC-39. House keep gene GAPDH was used as an internal
standard. The ratio for the mRNA was examined against GAPDH and was
expressed as mean 6 SE.
Western blot analysis. Renal cortical tissue samples were lysed with radi-
oimmunoprecipitation assay (RIPA) buffer, and proteins were extracted for
Western blot analysis as described previously (22). Brieﬂy, after protein was
transferred onto a nitrocellulose membrane, the membrane was incubated
overnight with primary antibodies against phospho-IkBa (ser32), phospho-p65
(ser276), phospho-Smad2, phospho-Smad3 (Cell Signaling Technology), ﬁ-
bronectin (Dako, Glostrup, Denmark), IkBa, p65, Smad7 (Santa Cruz Bio-
technology), and collagen I and collagen IV (Southern Biotech, Birmingham,
AL), followed by the LI-COR IRDye 800-labeled secondary antibodies (Rock-
land Immunochemicals, Gilbertsville, PA). The signals were detected with
Odyssey Infrared Imaging System (Li-COR Biosciences, Lincoln, NE) and
quantitated with ImageJ program (National Institutes of Health). The ratio for
the protein examined was normalized against GAPDH and expressed as
mean 6 SE.
Microalbumin urine and urinary creatinine analysis. Urinary micro-
albumin was detected by a competitive ELISA according to the manufacturer’s
protocol. Mouse urinary creatinine was measured by a colorimetric method
(QuantiChrom Creatinine Assay Kit, Hayward, CA). Although microalbuminuria
in rats was expressed as milligrams per 24 h, results of mouse microalbuminuria
were expressed as protein/urine creatinine (in mg/mg).
Histology and immunohistochemistry. Changes in renal morphology were
examined in methyl Carnoy’s ﬁxed, parafﬁn-embedded tissue sections (4 mm)
stained with the Periodic Acid–Schiff (PAS) method. Immnunostaining was
performed on parafﬁn sections using a microwave-based antigen retrieval
technique (29). The antibodies used in the study were as followed: ﬁbronectin
(Dako), collagen I and IV (Southern Tech), ICAM-1, MCP-1, IL-1b, and TNF-a
(Santa Cruz Biotechnology). After being immunostained with the secondary
antibodies, sections were developed with diaminobenzidine to produce a
brown color and counterstained with hematoxylin.
Quantitation of immunostaining was carried on coded slides as previously
described (18,22,23). Expression of collagen IV, ﬁbronectin, IL-1b, TNF-a,
MCP-1, and ICAM-1 in the entire cortical tubulointerstitium (a cross-section of
the kidney) was determined using the quantitative Image Analysis System
(AxioVision 4, Carl Zeiss, Germany) as previously described (22,23), whereas
expression in glomeruli was determined as described below. Brieﬂy, 20 glo-
meruli were randomly selected from each section and positive signals within
the selected glomerulus were highlighted, measured, and expressed as percent
positive area of the entire glomerulus. The number of phopsho-p65, phospho-
Smad2/3, F4/80
+, ED1
+ cells was counted in 20 consecutive glomeruli and
expressed as cells/glomerular cross-section, whereas positive cells in the
tubulointerstitium were counted under high-power ﬁelds (340) by means of
a 0.0625-mm
2 graticule ﬁtted in the eyepiece of the microscope and expressed
as cells per millimeters squared.
Statistical analysis. Data from studies were expressed as mean 6 SE. Sta-
tistical analyses were performed using one-way analysis of variance (ANOVA)
from the Prism Program (Prism 5.0 GraphPad Software, San Diego, CA) for
collagen matrix and inﬂammatory parameters in the rat model of diabetes,
whereas a two-way ANOVA was used for disease parameters obtained from
Smad7 WT and KO mice. In addition, a repeated ANOVA analysis was used for
albumin excretion analysis over the entire disease course in both mouse and
rat models.
RESULTS
Smad7 KO mice have aggravated diabetic renal
injury. After multiple low doses of STZ injection for 5
consequent days, both Smad7 KO and WT mice developed
equal levels of hyperglycemia (blood glucose 300–400
mg/dL) and body weight (38.99 6 1.60 vs. 41.60 6 1.42 g)
over the 24-week periods (Fig. 1A), indicating a comparable
damage with pancreatic islets of Smad7 WT and KO mice.
However, Smad7 KO mice developed more severe micro-
albuminuria than the WT mice over the 24-week disease
course (Fig. 1B). Pathologically, an increase in mesangial
matrix and thickness of glomerular basement membrane
was apparent in WT mice at week 24 of diabetes, which
was further enhanced in diabetic Smad7 KO mice (Fig.
1C).
Renal ﬁbrosis is enhanced in diabetic Smad7 KO mice.
As shown in Fig. 2, analysis with immunohistochemistry,
Western blot, and real-time PCR showed that deletion of
Smad7 largely increased collagen I (Fig. 2A–E), collagen IV
(Fig. 2F–K), and ﬁbronectin (Supplementary Fig. 2A–E)
expression and deposition in the diabetic kidney in both
glomeruli and tubulointerstitium when compared with the
diseased WT mice. Immunohistochemistry revealed that
although increased collagen I deposition was largely con-
ﬁned to the area of tubulointerstitium (Fig. 2C), an abun-
dant collagen IV and ﬁbronectin accumulation was noted
in both glomerular and tubulointerstitial areas and was
largely increased in Smad7 KO mice as shown in Fig. 2I–K
and in Supplementary Fig. 2C and D.
Renal inﬂammation was exacerbated in diabetic
Smad7 KO mice. Because inﬂammation is a critical pro-
cess in the development of diabetes complication (30,31),
we examined whether disruption of Smad7 gene inﬂuences
renal inﬂammation under diabetic conditions. As shown in
Fig. 3 and in Supplementary Fig. 3, immnunohistochemis-
try and real-time PCR revealed that when compared with
Smad7 WT mice, mice deﬁcient for Smad7 exhibited
a substantial increase in renal inﬂammation in both glo-
meruli and tubulointerstitium, resulting in a four- to sixfold
upregulation of proinﬂammatory cytokines IL-1b (Fig. 3A–
D) and TNF-a (Fig. 3E–H) and a two- to threefold increase
in adhesion molecule ICAM-1 (Supplementary Fig. 3A–D)
and chemokine MCP-1 (Supplementary Fig. 3E–H). En-
hanced expression of renal IL-1b, TNF-a, ICAM-1, and
MCP-1 in Smad7 KO mice was associated with a signiﬁcant
increase in macrophage inﬁltration (Fig. 3I and J).
Enhanced activation of TGF-b/Smad3 and NF-kB
signaling is a key mechanism by which deletion of
Smad7 promotes diabetic renal injury. We next in-
vestigated the mechanisms by which Smad7 KO mice
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studying the TGF-b/Smad and NF-kB signaling pathways.
We ﬁrst examined Smad7 expression in normal and di-
abetic mice. Western blot showed that whereas renal
Smad7 was not detectable in both normal and diabetic
Smad7 KO mice, it was signiﬁcantly decreased in WT mice
with diabetes (Fig. 4A and B). Inhibition of renal Smad7 in
diabetic WT mice resulted in a notable increase in phos-
phorylation of Smad2/3, which was further enhanced in
the diabetic kidney of Smad7 KO mice (Fig. 4C and D).
Further study by real-time PCR revealed that enhanced
activation of Smad3 signaling in Smad7 KO mice was as-
sociated with a marked increase in renal TGF-b1 mRNA
expression (Fig. 4E), demonstrating that deletion of Smad7
substantially enhanced TGF-b/Smad3 signaling in the di-
abetic kidney disease.
Similarly, enhanced renal inﬂammation in Smad7 KO
mice was associated with a further increase in NF-kB ac-
tivation in the diabetic kidney when compared with the
diabetic Smad7 WT mice (Fig. 4F–H). Indeed, when com-
pared with diabetic WT mice, deletion of Smad7 signiﬁ-
cantly enhanced NF-kB activation as demonstrated by
higher levels of phosphorylated IkBa and NF-kB/p65 (Fig.
4F–H).
Overexpression of renal Smad7 attenuates diabetic
kidney injury in a rat model of diabetes. To further
conﬁrm the protective role of Smad7 and develop a novel
therapy for diabetic kidney disease with Smad7, we de-
livered an inducible Smad7 gene into the left diabetic rat
kidney via the left renal artery using an ultrasound-
microbubble-mediated technique as previously described
(18). We ﬁrst determined the Smad7 gene transfection rate
FIG. 1. Diabetic kidney injury is enhanced in Smad7 KO mice. A: Blood glucose. Levels of blood glucose are signiﬁcantly increased at week 2 after
STZ injection and maintained at equal higher levels over the 24-week period in both Smad7 KO and WT mice. B: Urinary albumin exertion (UAE).
Smad7 KO mice had more severe microalbuminuria than the WT mice. C: Histology (PAS-stained sections). Data are expressed as mean 6 SE for
group of eight mice. #P , 0.05 vs. WT DM group by 2-way ANOVA. Magniﬁcation 3400. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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microbubble technique. As shown in Supplementary Fig. 4,
immunohistochemistry detected that endogenous Smad7
was high in the normal rat kidney in both glomerular and
tubulointerstitial cells (Supplementary Fig. 4B) but was
reduced in the diabetic kidney (Supplementary Fig. 4D). In
contrast, ultrasound-mediated Smad7 gene transfer into
the left kidney resulted in extremely higher levels of
Smad7 transgene expression as demonstrated by the
ﬁnding that almost all glomerular cells and tubulointer-
stitial cells were strongly positive for Flag-M2 and Smad7
protein (Supplementary Fig. 4E and F). Interestingly, a few
FIG. 2. Renal ﬁbrosis is enhanced in diabetic Smad7 KO mice. A–E: Collagen I (Col I) expression. F–K: Collagen IV (Col IV) expression. Results
show that when compared with the WT mice, Smad7 KO mice signiﬁcantly enhance renal collagen I and IV expression as demonstrated by Western
blot analysis (A, B, F, and G), immunohistochemistry (IHC; C and I) and quantitative analysis in glomeruli (J) and tubulointerstitium (D and K),
and real-time PCR at the mRNA level (E and H). Data represent mean 6 SE for groups of eight animals. *P , 0.05, **P , 0.01, ***P , 0.001 vs.
normal; #P , 0.05, ##P , 0.01, ###P , 0.001 vs. WT DM mice. Magniﬁcation 3400 (A and F). (A high-quality color representation of this ﬁgure is
available in the online issue.)
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Smad7 expression were also detected in both glomeruli
and tubulointerstitium in the right kidney (Supplementary
Fig. 4G and H), although no ultrasound energy was di-
rectly applied onto the right kidney.
We then examined the therapeutic effect of Smad7 on
diabetic kidney injury. As shown in Fig. 5A and B, gene
transfer of Smad7 attenuated microalbuminuria, although
levels of blood glucose remained high (.300 mg/dL).
Histopathologically, diabetic kidney treated with Smad7
also exhibited an improved ECM deposition in glomeruli
and tubulointerstitium when compared with the diabetic
rats treated with or without empty vector control (Fig. 5C).
Overexpression of renal Smad7 inhibits renal ﬁbrosis
and inﬂammation in a rat model of diabetes. Immu-
nohistochemistry and real-time PCR analysis showed that
FIG. 3. Renal inﬂammation is enhanced in diabetic Smad7 KO mice. A–D:I L - 1 b expression. E–H: TNF-a expression. I and J: Macrophages in-
ﬁltrating the glomerulus and the tubulointerstitium. Results show that when compared with the WT mice, Smad7 KO mice develop more severe
renal inﬂammation by enhancing renal IL-1b and TNF-a expression in glomeruli (A, B, E,a n dF) and in renal cortex (C and G) as demonstrated by
immunohistochemistry and mRNA expression real-time PCR (D and H). Data represent mean 6 SE for groups of eight animals. *P , 0.05, **P ,
0.01, ***P , 0.001 vs. normal; #P , 0.05, ##P , 0.01, ###P , 0.001 vs. WT DM mice. Magniﬁcation 3400 (A and E). (A high-quality color rep-
resentation of this ﬁgure is available in the online issue.)
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ﬁbrosis was developed in the diabetic kidney treated with
or without control empty vectors. This was demonstrated
b yas i g n i ﬁcant upregulation and accumulation of colla-
gen I (Fig. 6A–C), collagen IV (Fig. 6D–G), collagen III
(Supplementary Fig. 5A–C), and ﬁbronectin (Supplementary
Fig. 5D–F) in both glomeruli and tubulointerstitium. In
contrast, these ﬁbrotic changes were largely attenuated in
the diabetic kidney treated with Smad7 gene transfer (Fig. 6
and Supplementary Fig. 5).
Because deletion of Smad7 enhanced renal inﬂam-
mation in diabetic mice (Fig. 3 and Supplementary Fig. 3),
we examined whether overexpression of Smad7 reduces
renal inﬂammation in diabetic rats. Immunohistochemistry
and real-time PCR detected that signiﬁcant renal in-
ﬂammation was developed in diabetic rats treated with or
without empty control vectors, including upregulation of
IL-1b (Fig. 7A–D), TNF-a (Fig. 5E–H), ICAM-1 (Supplementary
Fig. 6A–D), MCP-1 (Supplementary Fig. 6E–H), and macro-
phage inﬁltration (Supplementary Fig. 7) in both glomer-
uli and tubulointerstitum. In contrast, overexpression of
Smad7 largely attenuated these inﬂammatory responses
(Fig. 7 and Supplementary Fig. 6) and blocked macro-
phage accumulation in glomeruli and tubulointerstitium in
the diabetic kidney (Supplementary Fig. 7).
Blockade of activation of TGF-b/Smad3 and NF-kB
s i g n a l i n gi sak e ym e c h a n i s mb yw h i c ho v e r e x p r e s s i o n
of Smad7 inhibits diabetic renal injury. As shown in
Fig. 8, immunohistochemistry revealed that a signiﬁcant
increase in activation of TGF-b/Smad signaling (Fig. 8A–C)
and NF-kB/p65 signaling (Fig. 8F–H) was apparent in the
diabetic rat kidney in both glomeruli and tubulointer-
stitium treated with or without control plasmids. In con-
trast, overexpression of Smad7 in the rat kidney of
diabetes substantially blocked activation of both TGF-b/
Smad and NF-kB/p65 signaling (Fig. 8A–C and F–H).
Further studies by real-time and Western blot analysis
detected that gene transfer of Smad7 resulted in higher
levels of Smad7 mRNA and protein expression in the di-
abetic rat kidney, thereby inhibiting Smad3, but not
Smad2, phosphorylation (Fig. 8D and E).
DISCUSSION
Increasing evidence has shown a critical role for the TGF-b
signaling in the development of diabetes complication (32).
The current study added new information for a protective
role of Smad7, a negative inhibitor of TGF-b/Smad signal-
ing, in diabetic kidney disease and provided new evidence
for prevention or treatment of diabetic kidney complica-
tion by targeting the TGF-b and NF-kB signaling pathways
with Smad7.
A signiﬁcant ﬁnding from the current study is that loss of
renal Smad7 may be a mechanism for the development of
diabetic kidney complication. This was supported by the
ﬁnding that renal Smad7 was signiﬁcantly decreased in 24-
week diabetic mice, which is consistent with other studies
in 17-week diabetic rats (33), in human mesangial cells
under high glucose conditions (34), in obstructive kidney
disease (18), and in remnant kidney disease (19). Because
FIG. 4. Enhanced TGF-b/Smad and NF-kB signaling pathways in di-
abetic Smad7 KO mice. Western blot analysis (A and B) shows that
when compared with normal WT mice, expression of Smad7 is signiﬁ-
cantly decreased in diabetic WT mice but undetectable in both normal
and diabetic KO mice. C and D: Phosphorylation of Smad3. Western blot
analysis shows an enhanced TGF-b/Smad3 signaling (p-Smad3) in di-
abetic Smad7 mice compared with diabetic WT mice. E: Real-time PCR
detects an increased renal TGF-b1 mRNA expression in diabetic Smad7
KO mice. F: Activation of NF-kB. Western blot analysis reveals that
an increased phosphorylation of IkBa in Smad7 KO mice is associated
with enhanced phosphorylation of NF-kB/p65 (p-p65). Note that phos-
phorylation causes degradation of IkBa and NF-kB/p65 protein,
respectively. J: Quantitation of phosphorylated IkBa (p-IkBa). H:
Quantitation of phosphorylated p65 (p-p65). Data represent mean 6 SE
for groups of eight animals. *P , 0.05, ***P , 0.001 vs. normal; #P ,
0.05, ##P , 0.01 vs. WT DM mice.
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and is capable of inducing a NF-kB inhibitor IkBa to block
NF-kB activation (14,16), therefore, loss of renal Smad7 in
the diabetic kidney may promote TGF-b/Smad-mediated
renal ﬁbrosis and NF-kB-driven inﬂammation. The ﬁndings
of enhanced diabetic kidney injury such as microalbu-
minuria, renal ﬁbrosis, and renal inﬂammation in Smad7
KO mice further supported this notion.
The current study revealed that antiﬁbrosis may be
a mechanism by which Smad7 protects kidneys from di-
abetic injury. Indeed, activation of TGF-b/Smad signaling
has been shown in the experimental and human diabetic
kidneys (35,36) and is responsible for ECM production in
vitro under high glucose and advanced glycation end
products conditions (36,37). The functional importance for
TGF-b signaling in diabetic kidney complication was
demonstrated in a mouse model of diabetes where de-
letion of Smad3, a key downstream mediator of TGF-b
signaling, inhibited diabetic renal injury (25,26). The cur-
rent study added new evidence for a role of Smad7 in
negatively regulating TGF-b/Smad-mediated diabetic kid-
ney damage as evidenced by the ﬁnding that loss of Smad7
sustained, but overexpression of Smad7 blocked, TGF-b/
Smad2/3-mediated renal injury in diabetes in terms of
microalbuminuria and collagen matrix (collagen I and IV
and ﬁbronectin) expression in the glumerulus and tubu-
lointerstitium. The protective role of Smad7 in diabetic
kidney ﬁbrosis is also consistent with previous ﬁndings
FIG. 5. Smad7 gene therapy attenuates diabetic kidney injury in rats. A: Blood glucose. B: Microalbuminuria. C: Histology. When compared with the
diabetic rats (DM) and empty vector control DM rats (VC), Smad7 gene therapy attenuates microalbuminuria and ECM deposition within the
glomerulus and tubulointerstitium. Data represent mean 6 SE for groups of six animals. **P , 0.01 vs. normal; ###P , 0.001 vs. DM and VC. (A
high-quality color representation of this ﬁgure is available in the online issue.)
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kidney that deletion of Smad7 promotes renal ﬁbrosis,
which is inhibited by overexpression of renal Smad7
(18,19,23).
Inhibition of renal inﬂammation may be another mech-
anism for a protective role of Smad7 in diabetic renal in-
jury. It is now clear that renal inﬂammation may also play
a role in diabetic kidney disease (30). A number of recent
studies have shown that many inﬂammatory mediators
such as IL-1b, TNF-a, MCP-1, ICAM-1, and macrophage
inﬁltration are increased in diabetes complications and
mice lacking these mediators are protected against di-
abetic renal injury (9,38–42). In line with these ﬁndings, we
also found that enhanced diabetic renal injury in Smad7
KO mice was associated with a signiﬁcant increase in renal
inﬂammation as evidenced by a further upregulation of
IL-1b, TNF-a, MCP-1, ICAM-1, and macrophage inﬁltration
when compared with the diabetic WT mice. In contrast,
overexpression of Smad7 in the kidney blocked the
development of renal inﬂammation. These observations
FIG. 6. Overexpression of renal Smad7 inhibits renal ﬁbrosis in diabetic rats. A–C: Collagen I expression. D–G: Collagen IV expression. Results
show that when compared with diabetic rats (DM) and diabetic rats with control vector treatment (VC), Smad7 gene transfer signiﬁcantly inhibits
renal collagen I and IV expression as demonstrated by immunohistochemistry (A, B,a n dD–F) and real-time PCR at the mRNA levels (C and G).
Data represent mean 6 SE for groups of six animals. *P , 0.05, **P , 0.01, ***P , 0.001 vs. normal; #P , 0.05, ###P , 0.001 vs. DM and VC mice.
Magniﬁcation 3200 (A and D). (A high-quality color representation of this ﬁgure is available in the online issue.)
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renal inﬂammation in diabetes.
NF-kB activation may be a critical mechanism in the
development of diabetic kidney disease (43). Indeed, NF-
kB is a critical signaling pathway of the inﬂammatory
cascade. The phosphorylation of the NF-kB inhibitor will
release the NF-kBp50/p65 subunits, resulting in nuclear
accumulation and transcriptional regulation of the target
genes (44). We have previously shown that Smad7 controls
inﬂammation by negatively regulating NF-kB signaling via
induction of IkBa, an inhibitor of NF-kB, thereby blocking
IkBa from degradation and preventing the activation of
NF-kB signaling in vivo and in vitro (14,20,23). In the cur-
rent study, we found that disruption of Smad7 enhanced the
phosphorylation of IkBa, thereby resulting in increased
activation of NF-kB/p65 signaling in the diabetic kidney. In
contrast, overexpression of renal Smad7 inhibited NF-kB
activation in the kidney with diabetes. All these ﬁndings
suggest that Smad7 may negatively regulate the NF-kB
signaling pathway to control renal inﬂammation in diabetic
FIG. 7. Overexpression of renal Smad7 inhibits renal inﬂammation in diabetic rats. A–D:I L - 1 b expression. E–H: TNF-a expression. Immunohis-
tochemistry and real-time PCR demonstrate that when compared with diabetic rats (DM) and diabetic rats treated with control vector (VC),
Smad7 gene transfer signiﬁcantly inhibits renal inﬂammation including IL-1b and TNF-a protein expression in glomeruli (A, B, E,a n dF) and
tubulointerstitium (C and G) and their mRNA expression (D and H). Data represent mean 6 SE for groups of six animals. *P , 0.05, **P , 0.01,
***P , 0.001 vs. normal; #P , 0.05, ##P , 0.01, ###P , 0.001 vs. DM and VC mice. Magniﬁcation 3400 (A and E). (A high-quality color repre-
sentation of this ﬁgure is available in the online issue.)
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598 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.orgFIG. 8. Overexpression of renal Smad7 blocks activation of the TGF-b/Smad and NF-kB signaling pathways in diabetic rats. A: Phosphorylated
Smad2/3 (p-Smad2/3) nuclear location. B and C: Quantitative analysis of nucleated p-Smad2/3 in glomeruli and tubulointerstitium. D: Renal Smad7
mRNA expression by real-time PCR. E: Western blot analysis of renal Smad7 and phosphorylation of Smad2 (p-Smad2) and Smad3 (p-Smad3). Note
that Smad7 gene transfer upregulates renal Smad7, thereby inhibiting phosphorylation of Smad3, but not Smad2. F: Phosphorylated NF-kB/p65
nuclear location. G and H: Quantitative analysis of phosphorylated NF-kB/p65 in the glomerulus and tubulointerstitium. Data represent mean 6 SE
for groups of six animals. *P , 0.05, **P , 0.01, ***P , 0.001 vs. normal; ##P , 0.05, ###P , 0.001 vs. DM and VC mice. Magniﬁcation 3400 (A and
F). (A high-quality color representation of this ﬁgure is available in the online issue.)
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but overexpression of renal Smad7 inhibited, renal in-
ﬂammation under diabetic conditions.
Taken together, results from the current study revealed
that Smad7 may have therapeutic potential for diabetic
kidney disease. The ﬁndings that ultrasound-mediated
Smad7 gene transfer into the left kidney produced a
marked inhibition of diabetic kidney injury were very im-
pressive. However, it should be pointed out that because
of the use of pan-ultrasound, the energy acted directly
onto the left kidney may also reach the right kidney in
some degree to inﬂuence the uptake of circulating Smad7
as evidenced by a small number of Flag-M2 positive cells,
resulting in mild to moderate Smad7 expression in the
right kidney. It should also be made aware that outcomes
from the current study in both mouse and rat models of
diabetes may not directly apply to the diabetic conditions
in humans. Nevertheless, the ﬁndings from this study may
provide new evidence for a better understanding of the
biological activities of Smad7 in diabetic kidney disease in
terms of protection against renal inﬂammation and ﬁbrosis.
In conclusion, Smad7 may play a protective role in diabetic
kidney complication. Blockade of TGF-b/Smad3-mediated
renal ﬁbrosis and NF-kB-driven renal inﬂammation may be
mechanisms by which Smad7 protects kidney from diabetic
injury. In addition, the ability of overexpression of renal
Smad7 to inhibit diabetic kidney disease indicates that
Smad7 may be a therapeutic agent for diabetic kidney
complication.
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